Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Systematic Review
23 November 2022

Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma

Authors: Sally D Miller, Greta Lozano-Ortega [email protected], Alex Mutebi, Owanate Briggs, Kavita Sail, Brian Elliott, and Anupama KalsekarAuthor Info & Affiliations
Volume 12, Number 1
https://doi.org/10.2217/cer-2022-0146
PDFFormats

Abstract

Aim: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR). Patients & methods: Systematically reviewed multiple databases through 22 July 2021. Analyzed variations in patient characteristics and their relationship with ORR across trials. Results: Among 17 included trials, key patient characteristics varied substantially: primary refractory (0–69%), refractory to last line of therapy (LOT) (12–100%), ≥2 prior LOTs (14–100%), ≥3 prior LOTs (0–64%), IPI ≥3 (23–73%), tumor stage III/IV (50–90%) and median age (56–74 years). ORRs varied substantially (25–83%), correlating with these characteristics. Conclusion: Differences in patient characteristics significantly contribute to the variability in ORR across these trials and should be considered when contextualizing efficacy data.

Supplementary Material

File (supplementary tables.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Cancer stat facts: common cancer types. https://seer.cancer.gov/statfacts/ (2022).
Google Scholar
2.
Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235–242 (2002).
PubMed
Google Scholar
3.
Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116(12), 2040–2045 (2010).
PubMed
Google Scholar
5.
Tilly H, Gomes Da Silva M, Vitolo U et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26(Suppl. 5), v116–v125 (2015).
PubMed
Google Scholar
6.
Salles GA, Pettengell R, Cordoba R, Długosz-Danecka M, Jurczak W, Tilly H. Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. Leuk. Lymph. 60(7), 1610–1625 (2019).
PubMed
Google Scholar
7.
Caimi PF, Ai W, Alderuccio JP et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, Phase 2 trial. Lancet Oncol. 22(6), 790–800 (2021).
PubMed
Google Scholar
• This study is one of the most recent studies published in this population and the only study meeting our inclusion criteria that reported CAR-T in enrolled patients.
8.
Hutchings M, Mous R, Clausen MR et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet 398(10306), 1157–1169 (2021).
PubMed
Google Scholar
9.
Thuresson P-O, Vander Velde N, Gupta P, Talbot J. A systematic review of the clinical efficacy of treatments in relapsed or refractory diffuse large B cell lymphoma. Adv. Ther. 37(12), 4877–489 (2020).
PubMed
Google Scholar
•• Highlighted the insufficiency of the published RCT data among transplant-ineligible DLBCL patients to establish the comparative efficacy of treatments via indirect treatment comparison and provided an impetus for this work.
10.
Sterne JaC, Savović J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).
PubMed
Google Scholar
11.
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J. Surg. 73(9), 712–716 (2003).
PubMed
Google Scholar
12.
Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth. Analg. 126(5), 1763–1768 (2018).
PubMed
Google Scholar
13.
El Gnaoui T, Dupuis J, Belhadj K et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann. Oncol. 18(8), 1363–1368 (2007).
PubMed
Google Scholar
14.
Lopez A, Gutierrez A, Palacios A et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a Phase II study. Eur. J. Haematol. 80(2), 127–132 (2008).
PubMed
Google Scholar
15.
Mounier N, El Gnaoui T, Tilly H et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A Phase II Lymphoma Study Association trial. Haematologica 98(11), 1726–1731 (2013).
PubMed
Google Scholar
16.
Ohmachi K, Niitsu N, Uchida T et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 31(17), 2103–2109 (2013).
PubMed
Google Scholar
17.
Sehn LH, Herrera AF, Flowers CR et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 38(2), 155–165 (2020).
PubMed
Google Scholar
• The pivotal trial supporting the approval of polatuzumab vedotin for R/R DLBCL; one of therapies for R/R DLBCL.
18.
Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann. Hematol. 93(3), 403–409 (2014).
PubMed
Google Scholar
19.
Terui Y, Rai S, Izutsu K et al. A Phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 112(7), 2845–2854 (2021).
PubMed
Google Scholar
20.
Abramson JS, Palomba ML, Gordon LI et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254), 839–852 (2020).
PubMed
Google Scholar
21.
Neelapu SS, Locke FL, Bartlett NL et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N. Engl. J. Med. 377(26), 2531–2544 (2017).
PubMed
Google Scholar
• The pivotal trial supporting the approval of axicabtagene ciloleucel for R/R DLBCL; one of therapies for R/R DLBCL.
22.
Schuster SJ, Bishop MR, Tam CS et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380(1), 45–56 (2019).
PubMed
Google Scholar
• The pivotal trial supporting the approval of axicabtagene ciloleucel for R/R DLBCL; one of therapies for R/R DLBCL.
23.
Salles G, Duell J, Barca EG et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, Phase 2 study. Lancet Oncol. 21(7), 978–988 (2020).
PubMed
Google Scholar
24.
Kalakonda N, Maerevoet M, Cavallo F et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 7(7), e511–e522 (2020).
PubMed
Google Scholar
25.
Pettengell R, Dlugosz-Danecka M, Andorsky D et al. Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). Brit. J. Haematol. 188(2), 240–248 (2020).
PubMed
Google Scholar
26.
Zinzani PL, Pellegrini C, Gandolfi L et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a Phase 2 trial. Clin. Lymph. Myeloma Leuk. 11(6), 462–466 (2011).
PubMed
Google Scholar
27.
Harting R, Venugopal P, Gregory SA, O'Brien T, Bogdanova E. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin. Lymph. Myeloma 7(6), 406–412 (2007).
PubMed
Google Scholar
28.
Papageorgiou ES, Tsirigotis P, Dimopoulos M et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. Eur. J. Haematol. 75(2), 124–129 (2005).
PubMed
Google Scholar
29.
Sehn LH, Hertzberg M, Opat S et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: updated results of a phase Ib/II randomized study and preliminary results of a single-arm extension. Blood 136(Suppl. 1), 17–19 (2020).
Google Scholar
30.
Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 17(4), 1244 (1999).
PubMed
Google Scholar
31.
Cheson BD, Fisher RI, Barrington SF et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32(27), 3059–3068 (2014).
PubMed
Google Scholar
32.
Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25(5), 579–586 (2007).
PubMed
Google Scholar
33.
Lin TL, Kuo MC, Shih LY et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann. Hematol. 91(9), 1383–1391 (2012).
PubMed
Google Scholar
34.
Crump M, Neelapu SS, Farooq U et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16), 1800–1808 (2017).
PubMed
Google Scholar
•• SCHOLAR-1 is the largest patient-level pooled analysis of response rates among patients with refractory DLBCL ant the results provide context for the findings of this review.
35.
Bannerji R, Arnason JE, Advani RH et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 9(5), e327–e339 (2022).
PubMed
Google Scholar
36.
Dickinson M, Carlo-Stella C, Morschhauser F et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥2 prior therapies: pivotal Phase II expansion results. J. Clin. Oncol. 40(Suppl. 16), 7500–7500 (2022).
Google Scholar
37.
Thieblemont C, Phillips T, Ghesquieres H et al. Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: a Phase 2 study. Presented at: The European Hematology Association Congress (2022).
Google Scholar
38.
National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567). Technology appraisal guidance. Available at: www.nice.org.uk/guidance/ta567 (2019).
Google Scholar
|